{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-075127","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-06-17T20:05:37+00:00","discovered_at":"2026-06-17T20:07:00.408876+00:00","generated_at":"2026-06-17T20:15:36.272295+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Regeneron shareholders elect Class II directors, approve auditor and advisory compensation at annual meeting","bullets":["All five Class II director nominees elected: Goldstein, Poon, Schenkein, Thompson, Zoghbi.","Ratification of PwC as independent auditor for FY 2026: 102.5M for, 6.4M against, 68.8K abstain.","Advisory vote on executive compensation approved: 96.5M for, 6.9M against, 105.5K abstain, 5.5M broker non-votes.","Meeting held June 12, 2026; results reported June 17, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-075127","json":"https://secwatch.observer/filing/0001104659-26-075127.json","markdown":"https://secwatch.observer/filing/0001104659-26-075127.md","text":"https://secwatch.observer/filing/0001104659-26-075127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/0001104659-26-075127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/tm2618117d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:15:36.272295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f5c38b8ce1ad461e325ec1bd231e2855356e7b6","claim":"REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 72,398,297 30,904,254 170,603 5,543,411 Christine A. Poon 79,409,070 24,004,880 59,204 5,543,411 David P. Schenkein, M.D. 99,241,219 4,180,107 51,828 5,543,411 Craig B. Thompson, M.D. 81,933,651 21,378,567 160,936 5,543,411 Huda Y. Zoghbi, M.D. 100,665,234 2,698,397 109,523 5,543,411","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/0001104659-26-075127-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"8f4499faa0c39f83ed7c1ee34d3ab53fd308d656","claim":"REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For: 102,503,788 Against: 6,443,958 Abstain: 68,819","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/0001104659-26-075127-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"aaad3b632d815d72d699d5c3dedbaae9c3bf47a9","claim":"REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes: For: 96,469,374 Against: 6,898,268 Abstain: 105,512 Broker Non-Votes: 5,543,411","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926075127/0001104659-26-075127-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}